Vascular Intervention Strategies Trial for Alzheimer's
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age50-75
SponsorUniversity of Southern California
About this trial
The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.
Eligibility criteria
Qualifiers
APOE ε4 carrier (homozygote or heterozygote)
LDL-C of 100-250 mg/dL
Systolic blood Pressure (SBP) 130-180 mm Hg
Age 50-75 years
Disqualifiers
One minute standing SBP < 110 mm Hg
Arm circumference prevents from accurate BP measurement with use of available devices
Lost weight of > 10% unintendedly (within the past 6 months),
Contraindications to blood pressure and cholesterol lowering medications
Trial design
Treatments tested in this trial
- Angiotensin Receptor Blockers (ARBs)
- Hydrophilic Statins or Non-Statin Alternative
Treatment groups
10 Participants
are divided into 1 treatment groupLocations
1Clinical Sciences Building (CSC)90033, Los AngelesCalifornia, United States
Sponsors and collaborators
University of Southern California
Lead sponsor
Source ClinicalTrials.gov